加入官方line@ 加入FB粉絲團
  • 免費註冊
  • 加入官方line@
  • 加入FB粉絲團

台股 » 個股 » 健亞 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

健亞

(4130)
可現股當沖
  • 股價
    24.35
  • 漲跌
    ▲0.30
  • 漲幅
    +1.25%
  • 成交量
    241張
  • 產業
    上櫃 生技醫療類股

  • 150人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
健亞 (4130)籌碼相關－富邦-和美 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效，來找出真正獲利的贏家所在券商分點，進而追蹤此贏家所操作的股票與軌跡。

股票投資新手教室：一秒知道是否上對大戶列車

富邦-和美 券商分點個股進出

富邦-和美 券商分點全部個股操作績效/獲利分析

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/04/26124.0500.0024.0512120.47%
2024/04/2500.00824.1124.10-8212-3.77%
2024/04/23124.1500.0024.2512180.46%
2024/04/1800.00124.3024.30-1215-0.46%
2024/04/1600.00424.1023.95-4216-1.85%
2024/04/15124.6500.0024.5512160.46%
2024/04/1000.00225.3025.30-2213-0.94%
2024/04/03125.0000.0025.0012100.48%
2024/03/28025.3500.0025.0502240.00%
2024/03/26025.2500.0024.7002260.00%
2024/03/25025.1700.0025.0002250.00%
2024/03/19124.9500.0024.9512310.43%
2024/03/15124.9500.0025.1012330.43%
2024/03/14125.2000.0025.2012340.43%
2024/03/13225.15725.1525.15-5236-2.11%
2024/03/12125.15225.1525.15-1237-0.42%
2024/03/11125.1000.0025.1012370.42%
2024/03/08125.3000.0025.0512410.41%
2024/03/06225.6800.0025.7522470.81%
2024/03/05425.8000.0025.7542461.62%
2024/03/04125.9500.0026.0012510.40%
2024/03/01526.16326.0826.3022560.78%
2024/02/27525.8800.0025.8052721.83%
2024/02/26125.75425.7025.80-3274-1.09%
2024/02/23725.64425.6525.6032731.10%
2024/02/22226.18826.1126.10-6271-2.21%
2024/02/20725.5700.0025.6072582.70%
2024/02/191725.7800.0025.50172596.54%
2024/02/15625.3400.0025.3562572.33%
2024/02/0200.00224.9024.90-2256-0.78%
2024/01/18025.1000.0025.0003330.00%
2023/11/2700.00528.1827.90-5321-1.56%
2023/11/2400.00227.2027.20-2303-0.66%
2023/11/22427.0300.0027.0543211.24%
2023/11/21227.0500.0027.0523450.58%
2023/11/14126.6500.0026.6513440.29%
2023/11/0900.00127.2027.25-1340-0.29%
2023/11/07127.80127.4527.2003580.00%
2023/11/03127.15127.0526.9003570.00%
2023/11/0200.00126.9026.60-1350-0.28%
2023/11/01126.7000.0026.8513460.29%
2023/10/31226.23125.9025.9013370.30%
2023/10/3000.00126.5026.40-1339-0.29%
2023/10/27126.4000.0026.5513320.30%
2023/10/26225.30125.4025.4013190.31%
2023/10/18125.7000.0025.2513690.27%
2023/10/1600.00526.3026.50-5375-1.33%
2023/10/13125.9500.0025.8513840.26%
2023/10/12125.8000.0025.8513940.25%
2023/10/06126.1500.0026.1514140.24%
2023/10/05125.9000.0026.2014290.23%
2023/09/27026.7000.0026.4004930.00%
2023/09/26126.4000.0026.4015020.20%
2023/09/2500.00627.0026.80-6509-1.18%
2023/09/20226.7500.0026.7525980.33%
2023/09/19227.0500.0027.0526150.33%
2023/09/14127.3000.0027.2516320.16%
2023/09/07227.1000.0027.0026750.30%
2023/09/06127.20527.4027.20-4688-0.58%
2023/08/2500.00228.3028.05-2776-0.26%
2023/08/143025.6000.0025.45301,0772.78%
2023/08/11026.8000.0026.6001,0740.00%
2023/08/101627.4400.0027.00161,0761.49%
2023/08/0700.00127.9527.85-11,129-0.09%
2023/08/04127.7500.0027.9011,1770.08%
2023/07/261027.7000.0027.75101,3490.74%
2023/07/2500.00528.1528.20-51,399-0.36%
2023/07/24327.7500.0027.7031,3970.21%
2023/07/211228.1100.0028.00121,3880.86%
2023/07/19229.0000.0029.0021,3820.14%
2023/07/181928.7300.0028.55191,3911.37%
2023/07/171329.3900.0029.30131,4120.92%
2023/07/12229.3000.0028.7521,4200.14%
2023/07/1100.00129.7029.40-11,416-0.07%
2023/07/0400.00130.2530.10-11,453-0.07%
2023/06/28130.05030.1530.2011,4030.07%
2023/06/27130.10129.8029.7001,3970.00%
2023/06/2000.005.129.8930.15-5.11,384-0.37%
2023/06/19529.35229.4029.3031,3730.22%
2023/06/121030.4000.0030.20101,3790.72%
2023/06/0100.00630.3230.80-61,499-0.40%
2023/05/31229.5500.0029.7521,4760.14%
2023/05/30629.4500.0029.2061,4750.41%
2023/05/2900.000.129.7529.85-0.11,473-0.01%
2023/05/2600.00230.1029.65-21,488-0.13%
2023/05/24331.70431.4831.45-11,446-0.07%
2023/05/2300.00931.1031.30-91,427-0.63%
2023/05/17328.4000.0029.0031,3240.23%
2023/05/15227.3000.0027.3021,4240.14%
2023/05/101030.20230.3030.3081,8230.44%
2023/05/0500.00229.8529.85-21,831-0.11%
2023/05/04230.30330.3330.45-11,824-0.05%
2023/05/0300.00129.9029.90-11,815-0.06%
2023/05/023730.773830.2030.20-11,799-0.06%
2023/04/28028.70229.0529.30-21,747-0.11%
2023/04/20228.5000.0027.9521,8580.11%
2023/04/19129.0000.0029.1011,8670.05%
2023/04/1400.00127.9527.95-12,101-0.05%
2023/04/13328.00227.9828.2512,1980.05%
2023/04/12127.903127.8127.90-302,262-1.33%
2023/04/1000.001027.0126.85-102,493-0.40%
新藥研發 浩鼎子公司抗癌新藥申請一期臨床 健亞明年完成試驗Anue鉅亨－2022/09/12
...詳全文
健亞轉投資浩宇超音波D針具追蹤系統 獲美台上市許可UDN聯合新聞網－2022/05/09
健亞（4130）今（9）日宣布，轉投資浩宇生醫公司開發的NAVIRFA（納維爾）超音波3D手術針具追蹤系統，雙雙取得美、......詳全文
健亞轉拓資浩宇NaviFUS®產品 首獲研究用途設備訂單UDN聯合新聞網－2021/03/15
健亞（4130）今（15）日宣布，轉投資的浩宇生醫，下半年將取得肝癌治療產品NAVIRFA®之美國510（k）及台灣二類......詳全文
健亞 相關文章